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Abstract: In this paper, we propose an innovative investment framework incorporating asset allocation 
and class diversification oriented specifically for the biotechnology industry. With growing interests and 
capitalization in multiple biotech markets, investors require a more dynamic method of managing their 
assets within individual portfolios for optimal return efficiency. By selecting a single firm representative 
of identified industry trends, analyzing financial metrics relevant to the suggested approaches, and 
assessing financial health, we developed an adaptable investment methodology. We also performed 
analyses of industrial viability and investigated the implications of the selected strategies, with which we 
were able to optimize our framework for versatile application within specialized biotech markets. 
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1. Introduction – Investment Strategies 
 
       Investors utilize investment strategies, which 
consist of a systematic plan of procedures and 
rules to adhere to, in order to guide the allocation 
of their assets among a diverse range of 
investments, allowing for capital expansion whilst 
minimizing financial risk within their portfolio. 
Strategies primarily depend on the type of 
investment and the profit goal of each investment, 
as strategists and investors seek to find the 
optimal trade-off between their profit objectives 
and portfolio safety.[1] Traditionally, company 
investments in other companies serve to the 
benefit of both ends, but one needs to be able to 
pare an agreement of personal interests while 
minimizing associated risk so that they are able to 
breakeven or make a significant profit.[2] The 
establishment of careful asset control and 
diversification strategies of preferred stocks, in 
conjunction with analysis of financial data, allows 
for investors to determine which selection 
provides the best competitive advantage to a 
company. These strategies, in other terms, can be 
viewed as a calculated protocol of investment 
management, which for strategists, analysts, and 
independent investors alike, offers an efficient 
method to plan for and increase probability of 
fiscal success. 
 
Although dynamic markets provide different 
opportunities and challenges, investors are able to 
choose from a wide array of possible strategies, 
and can modify or merge possible approaches to 
accommodate their intended investment objectives. 
For example, the branch of “passive” strategies 
emphasizes cautious investing, only buying and 
selling to develop steady profits over an extended 
period of time. However, by doing so, investors 
must resist the desire to trade their assets at times 
of market downturn and maintain resilience 
during market depreciation. Such an approach 
requires investors to have patience and put their 
faith in the market to gradually reach equilibrium. 
Strategies may depend on market behavior and 
volatility, but a general attitude should exist 
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within the investor. As mentioned before, 
investors can allow market forces to dictate their 
decisions, but can be more aggressive within the 
market and attempt to participate in day trading, 
also known as momentum trading, where the 
general performance of a company is analyzed 
and the decisions to invest in it are accordingly 
made. This approach increases the risk associated 
within the investment, as one makes bold trades 
and decisions, but the short-term returns may be 
rewarding if the proper methods are correctly 
implemented.  
 
As various tactics can be incorporated into one’s 
own investment approaches, a generalized 
structure of specialized techniques allows for the 
specification to a definite market. One such group 
of rapidly developing companies is the 
biotechnology enterprise, which harbors cutting 
edge research and great prospect in future 
financial expansion. Identifying this area of 
consistent growth, this paper develops a 
comprehensive framework for strategic biotech 
investments, primarily by synthesizing asset 
allocation and class diversification methodologies 
into a joint system refined for current markets, 
while also allowing for dynamic adaptability 
within the framework. 
   
2. Investigation of the Current 
Biotechnology Industry  
 
As defined by the Biotechnology Innovation 
Organization (BIO), biotechnology, also known as 
biotech, “harnesses cellular and biomolecular 
processes to develop technologies and products 
that help improve our lives and the health of our 
planet.”[3] Current developments in biotech are 
focused on combating global diseases and 
pandemics, optimizing environmental systems to 
reduce pollution, enhancing energy production 
and usage, improving manufacturing methods, 
and many other possible applications. The 
industry is relatively new, first launched by the 
discovery of DNA and the identification of its 
ability to be constructed and modified to 
accomplish specific objectives in 1973.[4] Since 
then, companies and enterprises have developed 
revolutionary products aimed at specific internal 
markets, and through progressive research,
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A representation of the relationship between annual volatility and annual 
return as presented by the Vanguard Group. Broad diversification can allow for the 
protection against the risks presented by owning individual securities. This further 
justifies the role that calculated asset allocation plays in both return and portfolio 
variability.[6]  
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strategic planning, and specialized marketing, 
have established critical roles in many larger areas 
for market capitalization. 
 
Pharmaceutical companies within the biotech 
industry have many specialized sectors, including 
bioinformatics and bioremediation.[5] Such a 
spectrum of particular objectives allows for 
investors to identify what technological 
developments within biotech has potential for 
significant expansion. The primary appeal of 
investing in biotech companies is the prospect of 
creating great returns from budding technologies, 
providing many opportunities for strategic 
investing. As seen in Figure 1, trends of an 
increase in annual volatility suggest an increased 
likelihood of greater profits, supplementing 
investors’ growing interest in biotech markets.[6] 
Products within this industry are capable of 
transitioning from minute market values to 
immense profits in a very short period of time. 
Small firms provide a chance of introducing 
products that could revolutionize specific areas of 
biotech, but the “high-risk, high-reward” 
sentiment should not be the only way these 
products are viewed through; patience and 
calculated speculation can provide investors with 
a safer, yet still effective approach for careful 
investing. 
 
With the rapid growth of multiple biotech markets, 
investors are taking greater interest in strategic 
short-term and long-term investing of the 
industry.[7] There are a few specific considerations 
that must be addressed prior to developing a 
dynamic framework that would allow for versatile 
and effective asset management. Based upon 
Porter’s 5 Forces Analysis, the first point of 
interest is understanding how new companies are 
able to enter the market.[8] Due to the biotech 
industry being composed of multiple smaller but 
developed companies, barriers to entry exist. As a 
result, only the most competitive and aggressive 
ventures are able to breakthrough, let alone 
succeed; such barriers, however, make it easier to 
identify companies with potential for rapid growth. 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Comparison of public company revenues and number of commercial 
leaders from the US and EU within the biotechnology industry, as reported by Ernst 
& Young (EY). Over the past 15 years, biotech markets have shown great surges in 
revenue and industrial growth, and are projected to continue expansion in the next 
decade. Widespread potential for market capitalization has attained the interest of 
investors who seek to develop versatile portfolios for maximum profit.[10]
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Accordingly, the wide availability of many 
biotech substitutes, specifically those that are 
easily made and readily accessible, introduce 
issues of price competition and should be 
investigated prior to any investment decision.  
 
Specialized versus non-specialized corporations 
should also be differentiated prior to developing a 
structured framework, as customer and 
corporation purchasing power is dependent upon 
the targeted biotech market. Just as customers 
hold bargaining power, suppliers also hold great 
control of their intended target and product 
distribution. In many cases, private ventures 
license their developed technologies to prevent 
sharing of their intellectual property: a central 
source of a company’s value. Lastly, the intense 
competition present in the biotech industry 
provides investors with an additional challenge, as 
they must carefully determine if a small venture 
suggesting possible expansion is more valuable 
than a larger, already established company. 
 
There are a few considerations that must be made 
to fully understand the current state of the biotech 
industry. As the NASDAQ Biotech Index has 
recently grown despite investors’ worry of 
volatility, many small-cap biotech firms have 
maintained attractive billion-dollar valuations, but 
not all of them exhibit accelerated growth as they 
once did. Many biotech firms still have multiple 
initial public offering (IPO) windows open due to 
the establishment of a few innovative technologies 
over the span of the past 5 years.[9] As shown in 
Figure 2, public company revenues in both the US 
and European countries have significantly grown 
over the past decade. This can partly be attributed 
to recent discoveries in CRISPR, epigenetics, and 
gene therapy technologies, which market analysts 
believe will continue to allow for expansion of 
biotech IPOs within the coming years.[10] There 
have also been multiple new revolutionary 
therapeutic systems, including Zydelig, CAR-T, 
Solvavdi, and anti-PCSK9s, which have 
introduced over 3,400 active clinical stage 
projects; from these projects, nearly 70% are 
helmed by small, newer companies.[11] Compared 
to past cycles, the current industry pipeline has 
delivered on its potential, and provides an 
appealing source for deep investment. With over 
2,500 current biotech companies within the US 
alone, multiple financial metrics, primarily 
surrounding company assets, have also allowed 
for the development of new dynamic investment 
strategies.[12] In the present state of market 
capitalization possible in the biotech industry, 
such calculated approaches can provide investors 
with efficient and adaptable methods of 
establishing both short-term and long-term 
portfolio growth. 
 
3. Application of Potential Asset 
Allocation Strategies 
 
       Dynamic asset allocation refers to the 
integrated role of both passive and active 
strategies to be able to coincide with business 
decisions and ventures. Specifically, it involves 
what assets should be held, sold, and purchased to 
maximize financial security and reward. Financial 
ratios are key in these aspects, as they can 
combine the key data provided by the company to 
determine health, current financial condition, and 
projected prosperity. The P/E ratio utilizes the 
cash flow statement, balance sheet, and income 
statement to provide a comprehensive quantitative 
view of the company. When the inverse squared 
of this value is taken, the earnings yield may be 
calculated, an important valuation index directly 
proportional to the type of returns that a business 
makes.  
 
However, decisions involving the mentioned 
dynamic asset allocation methodology are 
complex and require a deeper look in order to 
eliminate decisions that may negatively impact 
current asset holdings. Thus, knowing which 
stocks to buy and when to allocate them is 
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essential in having investment success. The three 
main asset classes are equities, bonds, and cash 
equivalents, each of which allows for the asset 
mix to be brought back to the long term objective 
via dynamic allocation. This accordingly reduces 
risks in asset fluctuation while also providing 
returns much greater than the desired benchmark. 
But in order to optimize the different risk and 
return characteristics for each individual class 
equivalent, conservative selections must be made; 
adjustments to asset allocation within portfolios 
must also be conservative in order to retain 
distance from volatility, something associated 
with alternative equity investing. Such attention to 
detail and appropriate judgement is crucial for 
making optimal investment decisions. 
 
In order to provide a quantitative application of 
asset allocation, a biotechnology company must 
be analyzed first by looking at the trend of assets 
over time, how it compares to industry standards, 
and its ability to easily liquidize. A sample 
industry in the market can be analyzed to provide 
a representative sample of the behavior of the 
market as a whole, and the efficiency of asset 
allocation can be assessed. Take for example the 
following leader in the biotechnology industry, 
Gilead Science Inc., and their balance sheets for 
the past four years. [13]  
 
Due to the 107 billion-market cap and maturity of 
this biotech company, Gilead Sciences Inc. is at 
low risk at bankruptcy, and can maintain a low 
liquidity as a result. Dissecting the assets via 
vertical analyses is a major piece of evidence for 
further allocation; the decreasing liquidity and 
quick and current ratios may be seen as the cash 
and other equivalents were curbed in 2016 to 
about 70 percent of the previous year and as well 
as a decrease in inventory. Furthermore, there are 
small increases in other current assets and an 
overall 4 million decrease in current assets. Upon 
closer inspection, the money has been allocated to 
other long term assets such long-term investments, 
with a 20 times increase over the course of only 
two fiscal years (2014-2016), and also towards 
shareholders via dividends. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Balance sheet of Gilead Science Inc. for current and fixed assets over 4 
year growth period. This statement provides a comprehensive overview of the 
largest individual asset components within the biotech company. By understanding 
the central asset distribution of Gilead, which is representative of multiple growth 
trends present in many biotech markets, a framework that relies most heavily on 
asset management can be developed. 
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Although it is crucial to instill trust within 
investors, Gilead Sciences may have to allocate 
money towards more of its more liquid assets and 
cut back on the amount of dividends as the 
company is diversifying to the point where growth 
is stagnant since too much money is given back to 
the investors. Furthermore, they should 
supplement this allocation with less equity 
financing and more debt financing as equity 
financing provides too many ownership shares 
into the market, which could backfire and in 
extreme cases, allow shareholders to effectively 
take hold of the company. Taking on debt 
financing is effective due to the low interest rates 
and especially the good financial standing of the 
market, putting it at less risk of bankruptcy. Such 
effective allocation can provide remedies to three 
major problems in biotechnology industries in 
general: a decrease in company growth, an 
abundance of competing biotechnology, and an 
increase in sentiments towards medical costs for 
American citizens. The repercussions of the 
aforementioned asset allocation strategies may be 
applied to each of these problems. 
 
Firstly, asset allocation can assist in reversing the 
stagnant growth or deterioration of a company. 
For example, Gilead Sciences has been increasing 
in total assets at a rapid rate; however, the 
allocation towards more long term and intangible 
assets has had a heavy toll on the company in the 
previous two years as they have been stockpiling 
on their current liabilities, with decreasing current 
assets to match them.[14] What this can result in is 
a liquidity crisis, in addition to further financing 
through debt or equity financing to pay off the 
liabilities. This may induce the negative 
consequences of both types of financing to a great 
extent. Excessive loans may have to be payed 
constantly if debt financing is chosen, and with a 
higher interest rate, it can be burdensome for 
biotechnology companies. Through equity 
financing, more company shares may be in the 
biotechnology market to the point where the 
increasing amount of investors has too much of a 
hold on the company, and the diversification 
shares too much of the company’s profit. 
 
The biotechnology market is expanding given 
growing innovation. As a result, it has engendered 
the emergence of other large companies in the 
market and many startups, changing the 
biotechnology market from a slight oligarchy to a 
competitive one.[15] Accordingly, biotechnology 
giants like Gilead Sciences Inc. and Amgen Inc. 
are gaining competition to rival their products, 
decreasing their sales. The minimal price control 
they exerted is then eliminated, forcing them to 
decrease them to have sales for sufficient profit. 
This is reflected quantitatively through the 
decrease in gross profit of Gilead Sciences Inc. on 
its annual income sheet by 2 million dollars in the 
past year, compared to continued increases in the 
years prior. Asset allocation for stockpiling on 
more liquid assets is effective due to the 
decreasing income. With not as much income 
generated as before by major biotechnology 
companies, much has to be allocated to cash and 
accounts receivable; this is attributed to the fact 
that the liabilities are still increasing at a constant 
rate. If such allocation does not take place, a 
liquidity crisis could cause the company to 
withdraw or convert long-term bonds and fixed 
assets to quick cash - an expensive and unfeasible 
process. 
 
Finally, the necessity of a strategy change in the 
biotechnology industry is reflected through 
increasing sentiments against biotech markets via 
fundamental and sentiment analysis. With the 
skepticism of new drugs and GMOs, the public 
has been induced to stray from such products, 
harming the sales of biotechnology companies. [16]  
 
In curbing long term repercussions of the growing 
biotechnology industry, assisting in maximizing 
assets and revenue, and assisting long-term 
company growth, asset allocation has been an 
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efficient method. Not only will the upwards trend 
in this industry be beneficial for the company 
owners, but also for the investors of the company, 
as it will instill trust within them (primarily 
through the increased dividends provided from 
company growth, increasing earnings per share). 
Although asset allocation is effective, pairing it 
with class diversification strategies make it an a 
even more dynamic methodology, which will be 
presented in the following sections.  
 
4. Application of Potential Class 
Diversification Strategies 
 
Asset class diversification provides investors 
with the ability to reduce overall investment risk 
and avoid asset damage by mixing a variety of 
investments within a portfolio. By doing so, 
investors are able to effectively control risk 
management of their portfolios through calculated 
allocation, increase the possibility of a greater 
profit margin, and minimize the possibility of 
widespread loss. There are two primary methods 
of asset class diversification: horizontal and 
vertical. Horizontal diversification includes 
investing in assets of similar types or 
classification, while vertical diversification 
involves investing in assets of varied classes. 
Within the entire range of more specialized 
diversification strategies, however, the asset class 
is a characteristic that is widely overlooked. 
Investors have accordingly understood that 
singular selection of asset classes within a 
portfolio is much more important than identifying 
individual assets or even market timing.[17] The 
dynamic freedom specific class selection provides 
is a viable strategy that can allow for a broader 
view for any investment framework. 
 
The safest and most reliable approach to 
implementing class diversification strategies is to 
distribute assets broadly within a portfolio. 
Effective diversification requires deep assortment 
across multiple classes, including large-cap and 
small-cap stocks, corporate and government bonds, 
and international and emerging market stocks. 
However, selective diversification must be made 
to identify the most viable and least volatile 
subsector for each given market. In the case of the 
biotechnology industry, in which new, highly 
volatile products suggest short-term large profits 
and losses, the role of a specific asset must be 
understood prior to investment. For example, 
investors looking to maximize profits, high-yield 
bonds are most suitable in complementing 
stationary holdings, despite their increased risk. 
Additionally, despite some general variation in 
weak and strong performances, commodities and 
their dissociation from certain classes allow for 
them to serve as useful class portfolio diversifiers. 
In conjunction with one another, deeper 
approaches to wide class diversification increases 
potential for better long-term performance whilst 
retaining minimal risk.  
 
The implementation of class diversification 
extends from the previous individual asset 
allocation, but rather than traditional short term 
assets, it diversifies the use of other financial 
assets in the market such as stocks, bonds, and 
commodities (the main classes). In the case of a 
growing biotechnology market, diversification of 
stocks is crucial in dictating how a company 
performs in the face of a recession or expansion. 
We again take Gilead Sciences as the 
representative company of the industry and 
analyze its market in a 52-week period with 
regards to earnings per share and shares 
outstanding, as illustrated in Figure 4.[18]  
 
Simple moving averages over the course of 20 and 
50 days were added, as indicated by the green and 
black lines on the stock prices. The intersection 
indicates change in the direction of the stock, and 
although there has been a cumulative increase 
from $71.65 to $85.1 over the course of only a 
few weeks, the two moving averages are set to 
intersect in the near future, indicating a decrease. 
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This is where class diversification comes in: in 
order to rival the setback, Gilead Sciences, along 
with other biotechnology giants, must be able to 
invest in other leading startups and increase their 
investments class. Additionally, they have to be 
mindful of the economic effects that an integrated 
economy has (with the UK and Europe), 
increasing the frequency of burst of economic 
growth and recessions. In a conditional 
inflationary environment, commodities and cash 
asset classes should be allocated more carefully 
compared to long-term bonds, which are more 
beneficial in a deflationary environment. This 
shows that asset class diversification is not static, 
and rather highly dynamic, especially in new 
markets with increasingly diverse innovations and 
products that are quick to change.  
 
 
 
Figure 4. Functional market evaluations over a 52-week period beginning on 
October 1st for Gilead Sciences Inc., a leading biotechnology firm. Illustrated are 
simple moving averages over 20 and 50 days, integrated with a changing price of 
the stock over the course of the year.[18] 
 
 
Ideal class diversification is able to accommodate 
for the increasing competition in the 
biotechnology industry and can help in increasing 
the amount of returns the company receives in the 
long term, even if there are minimal expenses 
from transactions in allocation. Through the 
allocation of stocks and bonds, the company is 
able to diversify further through more long-term 
financial assets and also retain some short-term 
assets in order to pay off current liquidities. 
Combining this with individual asset allocation, 
asset class diversification can assist in increasing 
the growth of the company, maintain a high 
liquidity with regard to economic recessions, and 
counter the recessions on the biotechnology 
industry from fundamental crises concerning the 
products and the costs to citizens.  
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Figure 5. Increase in Gilead Science Inc. and other lead biotechnology firms in 
terms of prices as represented by percentages. This is a direct consequence of 
effective asset allocation and class diversification of long-term stocks.[19] 
 
 
5. Development of a Market-Oriented 
Investment Framework 
 
       Although the strategies for the biotechnology 
industry have been identified, a framework must 
be developed and applied in order to identify what 
individual asset allocation and asset class 
diversification should take place. In order to 
determine what percentage of total assets each 
asset is worth, vertical analysis of the balance 
sheet can provide an accurate measure. In the 
aforementioned Gilead Sciences Inc. scenario, one 
may notice a heavy increase in liquid assets such 
as net receivables in cash during 2014 
(approximately 20% increase in cash). However, 
the percentage of total assets in cash was cut in 
half over the course of two years, displaying the 
decreasing liquidity.  
 
Although it is a lead company, storing away into 
long-term assets may not be an efficient move as a  
 
 
 
 
liquidity crisis may strike. Moreover, the 
decreasing revenue from $7,794 to $6,505 from 
2015 to 2016 and corresponding decreasing in the 
EPS from 2.53 to 2.05 signifies decreasing trust in 
the company.[20] In order to instill trust within its 
investors and maintain a fair share of equity 
financing, assets must be allocated in four ways:  
1) more allocation from intangible to long term 
investments, 2) transfer of revenue directly into 
cash and cash equivalents for increasing liquidity 
(to counter the decrease in the current and quick 
ratios), 3) increase in dividends to instill trusts 
within key investors, and 4) increase in the asset 
class of long-term stocks and bonds to fully utilize 
the time value of money in order to promote 
growth, which relies on the future boom of the 
biotechnology industry and the subsequent 
increasing revenue. These strategies must also be 
dynamically coordinated depending on external 
factors as well as recessions and expansions, 
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fundamental attacks on the products of 
biotechnology industries from politicians, and 
increasing competition or entry of startups 
(change in the Herfindahl-Hirschmann index to 
determine competitiveness of the market). 
Effectively, combining such strategies along with 
the vigilance of market timing and stock 
directions can assist a company in devising an 
efficient and effective portfolio in the 
biotechnology industry so that they can compete 
with other companies.  
 
Our optimized framework provides investors with 
a dynamic approach of developing their 
investment strategies specifically for multiple 
biotech markets. As it is effective in taking 
advantage of widespread market capitalization as 
exhibited throughout the biotech industry, it also 
retains financial stability and reduces likelihood of 
large loss despite market volatility. Additional 
strategies can be incorporated into our framework 
in future studies, which may allow for even 
further improved investment versatility. By doing 
so, not only would dynamic asset allocation and 
class diversification strategies be present, but 
supplemental approaches such as momentum 
selectivity or pairs trading would continue to 
improve the effectiveness and efficiency of the 
framework. 
 
 
 
Figure 6. Optimized summary framework dissecting the different strategies and 
implementation of various asset allocations. Provides a plan for analysts to follow 
and apply. Initially starts with interpreting the driving problem behind the 
biotechnology firm under inspection and then proceeds with diversification and 
allocation of assets and asset classes to finally devise a solution through financial 
metrics analysis. 
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